Last $0.02 USD
Change Today +0.001 / 4.55%
Volume 141.0K
MYMX On Other Exchanges
As of 1:51 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

mymetics corp (MYMX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - $0.08
52 Week Low
01/26/15 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYMETICS CORP (MYMX)

Related News

No related news articles were found.

mymetics corp (MYMX) Related Businessweek News

No Related Businessweek News Found

mymetics corp (MYMX) Details

Mymetics Corporation, a vaccine company, develops vaccines that focus on the mucosal layer as a first line of defense against viruses entering the blood stream. The company also develops virosomes as a vaccine delivery platform. Its product pipeline consists of five proprietary vaccines in development for the prevention and treatment of human immunodeficiency virus type 1, malaria, herpes simplex virus type I and II, respiratory syncytial virus, and intra-nasal influenza. The company was founded in 1990 and is based in Epalinges, Switzerland.

10 Employees
Last Reported Date: 11/13/14
Founded in 1990

mymetics corp (MYMX) Top Compensated Officers

Chief Executive Officer, President, Chief Ope...
Total Annual Compensation: €216.0K
Chief Scientific Officer
Total Annual Compensation: €216.0K
Compensation as of Fiscal Year 2013.

mymetics corp (MYMX) Key Developments

Mymetics Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Mymetics Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

PATH Malaria Vaccine Initiative Chooses Mymetics Corporation to Develop and Produce Virosome Based Vaccine Formulations for Malaria Transmission-Blocking Vaccine Candidate

Mymetics Corporation announced that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. Mymetics' proprietary virosome technology platform and its specialist virosome know-how has been selected to develop an innovative Malaria transmission-blocking vaccine candidate in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). These new virosome vaccine candidates will each incorporate two different malaria parasite proteins supplied by LMIV and will be then separately tested in animal studies. The project will start in November 2014, and preclinical results are expected by early 2016. If this study is successful, the next step could be to prepare for clinical trials for a malaria transmission-blocking virosome vaccine and also explore the possibilities to combine this vaccine with other malaria vaccine candidates which are focused on other aspects of preventing malaria.

Mymetics Corporation to Enter New Preclinical Trial of HIV-1

Mymetics Corporation announced that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial. With its HIV-1 (human immunodeficiency virus type 1) vaccine candidate, produced through its proprietary virosome technology and judicious antigen design, Mymetics aims to provide both a first line of defense through mucosal protection as well as a second line of defense against infection through the generation of blood antibodies. The new trial, to begin in October 2014, will involve 36 rhesus monkeys (n=12 per group) and compare two antigen vaccination regimens with placebo, followed by intra-vaginal challenges with live virus that carries an envelope that differs from the one in the vaccine preparation. Results are expected at the end of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYMX:US $0.02 USD +0.001

MYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYMX.
View Industry Companies

Industry Analysis


Industry Average

Valuation MYMX Industry Range
Price/Earnings 73.6x
Price/Sales 0.9x
Price/Book NM Not Meaningful
Price/Cash Flow 52.9x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYMETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at